CollPlant Biotechnologies (CLGN) CEO Tal Yehiel details option and RSU holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
CollPlant Biotechnologies Ltd director and Chief Executive Officer Tal Yehiel filed an initial ownership report. The filing lists direct holdings of options to purchase Ordinary Shares, including grants exercisable at $4.0200 and $6.3900 per share with expirations between 2028 and 2032, covering 75,000, 37,800, 81,266 and 100,000 underlying shares. Yehiel also reports 31,137 Ordinary Shares and 80,000 restricted share units, of which 25,000 are vested and 55,000 are scheduled to vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, subject to continued service. Certain awards are held through a trustee to qualify for Israeli Section 102 tax benefits.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Tal Yehiel
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
Holdings After Transaction:
Options to Purchase Ordinary Shares — 75,000 shares (Direct);
Ordinary Shares — 31,137 shares (Direct);
Restricted Share Units — 80,000 shares (Direct)
Footnotes (1)
- To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee. Of the restricted share units reported herein, 25,000 units are vested, and the remaining 55,000 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date. Fully vested and exercisable. 93,750 options are fully vested and exercisable and the remaining 6,250 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
FAQ
What does the Form 3 filing show for CollPlant Biotechnologies (CLGN) CEO Tal Yehiel?
The Form 3 shows Tal Yehiel’s initial ownership in CollPlant, including options, ordinary shares, and restricted share units. It establishes his starting equity position as director and Chief Executive Officer, rather than reporting any new share purchases or sales.
How many options does the CLGN CEO report holding in this Form 3?
Tal Yehiel reports several option grants to purchase CollPlant Ordinary Shares, including awards exercisable at $4.0200 and $6.3900 per share. These cover 75,000, 37,800, 81,266 and 100,000 underlying shares, with expiration dates between 2028 and 2032.
Why are some CollPlant (CLGN) equity awards held through a trustee?
The filing explains that certain securities issued to employees or directors must be registered in a trustee’s name. This structure is required to qualify for specific tax benefits under Section 102 of the Israeli Tax Ordinance for CollPlant’s share ownership and option plans.
Does this CollPlant (CLGN) Form 3 indicate insider buying or selling activity?
No, the Form 3 functions as an initial ownership statement for Tal Yehiel. It records existing holdings in options, ordinary shares, and restricted share units, without reporting new open-market purchases, sales, or other transactional changes in his equity position.